Congress mandates fast-track drug access for patients denied by insurers

What it does

This bill requires health insurance plans to create a clear, fast process for patients and doctors to request exceptions to 'step therapy' protocols—rules that force patients to try cheaper drugs first before insurers will cover the prescribed medication. If a patient meets one of six defined circumstances (prior drugs failed, delay would cause harm, contraindication, loss of function, or prior approval elsewhere), the plan must approve the exception within 72 hours (or 24 hours in emergencies) and cover the requested drug for at least one year. Plans must report annually to the Department of Labor on exception requests, approvals, and denials.

Why we flagged it

The bill's operative mechanism is a procedural right—it mandates a transparent exception process for step therapy denials. It does not ban step therapy itself, but constrains insurer discretion and creates enforceable timelines and criteria for exceptions, shifting leverage toward patients and prescribers.

What the text implies

• Reporting requirements may expose patterns in step therapy denials by medical specialty and condition, creating public data that could inform future regulation or litigation against insurers.
• The 'other circumstances' catch-all in subsection (b)(6) delegates authority to the Secretary of Labor to expand exception grounds post-enactment, potentially broadening patient access beyond the six enumerated categories.

The full analysis lists 5 implications of this text.

Who stands to gain

pharmaceutical manufacturers (brand-name and specialty drugs); patients requiring non-preferred medications; prescribers (reduced administrative burden from step therapy denials)